icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
LakDdD5m4r9HCkC5